Related Experiment Video
Updated: Aug 11, 2026
07:10
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
Published on: April 21, 2019
15.9K
Serum sRAGE as a potential biomarker for pediatric bronchiolitis: a pilot study
Alberto García-Salido1, Gonzalo Oñoro, Gustavo J Melen
1Pediatric Critical Care Unit, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo 65, Madrid, Spain, citopensis@yahoo.es.
Lung
|October 31, 2014
Summary
Serum soluble receptor for advanced glycation end product (sRAGE) levels were elevated in children with severe bronchiolitis. sRAGE showed an inverse correlation with disease severity, suggesting its potential as a biomarker.
Area of Science:
- Pediatric Pulmonology
- Critical Care Medicine
- Biomarker Research
Background:
- Traditional inflammatory biomarkers inadequately assess bronchiolitis severity.
- Receptor for advanced glycation end product (RAGE) and its soluble isoforms (sRAGE) are implicated in lung injury pathogenesis.
Purpose of the Study:
- To evaluate serum sRAGE levels in children with severe bronchiolitis admitted to the pediatric intensive care unit (PICU).
- To investigate the correlation between sRAGE levels and clinical evolution and traditional biomarkers in bronchiolitis.
Main Methods:
- Prospective, observational study including 37 children with bronchiolitis and 43 healthy controls.
- Assessed serum sRAGE levels and compared them between patients and controls.
- Analyzed the relationship between sRAGE levels and clinical severity scores, respiratory support, and inflammatory markers (WBC, neutrophils, CRP, procalcitonin).
Main Results:
- Mean serum sRAGE levels were significantly higher in bronchiolitis patients at PICU admission compared to controls (1,215.7 ± 535 vs 849 ± 579 pg/ml).
- A significant inverse correlation was observed between serum sRAGE levels and the Wood-Downes Score at admission (p = 0.02).
Conclusions:
- Serum sRAGE levels may be elevated in pediatric patients with bronchiolitis.
- Further large-scale clinical studies are needed to confirm sRAGE's role as a biomarker for bronchiolitis inflammation and/or lung injury.
